|Bid||1.520 x 900|
|Ask||1.530 x 2900|
|Day's range||1.500 - 1.540|
|52-week range||0.750 - 2.550|
|PE ratio (TTM)||N/A|
|Earnings date||8 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.67|
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
The Cupertino, California-based company said it had a loss of 5 cents per share. The specialty pharmaceutical company posted revenue of $3.5 million in the period. In the final minutes of trading on Wednesday, ...
On a per-share basis, the Cupertino, California-based company said it had net income of 5 cents. The specialty pharmaceutical company posted revenue of $19.5 million in the period, which topped Street ...
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...